Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Biography
Dr. Melinda Telli is an Associate Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine, Director of the Breast Cancer Program at the Stanford Cancer Institute and Associate Director of the Stanford Women's Cancer Center. Dr. Telli’s research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Her work has focused on the validation of homologous recombination deficiency biomarkers to help identify patients with sporadic triple-negative breast cancer that may specifically derive benefit from DNA repair defect-targeted therapies. In addition to her involvement in the clinical development of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers, she has also explored the use of ‘beyond BRCA’ DNA repair gene mutations as potential biomarkers to select patients for PARP inhibitor therapy in the advanced disease setting.
Dr. Telli received her undergraduate degree from the University of Pennsylvania Magna Cum Laude and medical degree from George Washington University with Distinction. She completed internship and residency in Internal Medicine at Stanford University, and then stayed at Stanford to pursue fellowship training in Medical Oncology. She has served on numerous American Society of Clinical Oncology Committees and currently serves as a Komen Scholar, member of the National Comprehensive Cancer Network Breast Cancer Guideline Panel and member of the Journal of Clinical Oncology Editorial Board. Dr. Telli is the recipient of a Susan G. Komen for the Cure Translational Postdoctoral Fellowship Award (2008), American Society of Clinical Oncology Young Investigator Award (2009), Susan G. Komen for the Cure Leadership Award (2015 and 2018), Triple Negative Breast Cancer Foundation Hero Award (2018) and Komen SF Bay Area Visionary Award (2019). She has garnered multiple teaching accolades and is a repeat recipient of the Stanford Division of Oncology Teaching Award.
Dr. Telli received her undergraduate degree from the University of Pennsylvania Magna Cum Laude and medical degree from George Washington University with Distinction. She completed internship and residency in Internal Medicine at Stanford University, and then stayed at Stanford to pursue fellowship training in Medical Oncology. She has served on numerous American Society of Clinical Oncology Committees and currently serves as a Komen Scholar, member of the National Comprehensive Cancer Network Breast Cancer Guideline Panel and member of the Journal of Clinical Oncology Editorial Board. Dr. Telli is the recipient of a Susan G. Komen for the Cure Translational Postdoctoral Fellowship Award (2008), American Society of Clinical Oncology Young Investigator Award (2009), Susan G. Komen for the Cure Leadership Award (2015 and 2018), Triple Negative Breast Cancer Foundation Hero Award (2018) and Komen SF Bay Area Visionary Award (2019). She has garnered multiple teaching accolades and is a repeat recipient of the Stanford Division of Oncology Teaching Award.
View Full Biography »
Professional Summary
Professional Education
- B.A., University of Pennsylvania, Biology, with Distinction (1996)
- M.D., George Washington University, Medicine, with Distinction (2002)
- Residency, Stanford University, Internal Medicine (2005)
- Fellowship, Stanford University, Medical Oncology (2008)
- Board Certification, American Board of Internal Medicine, Internal Medicine (2015)
- Board Certification, American Board of Internal Medicine, Medical Oncology (2018)
- Board Certification: American Board of Internal Medicine, Internal Medicine (2005)
- Board Certification: American Board of Internal Medicine, Medical Oncology (2008)
Honors & Awards
- Career Catalyst Research Award, Susan G. Komen for the Cure (2012)
- Champion Award, Triple Step Toward the Cure (2015)
- Fellowship Award, Susan G. Komen for the Cure (2008)
- Hero Award, Triple Negative Breast Cancer Foundation (2018)
- Komen Leadership Award, Susan G. Komen for the Cure (2015)
- Merit Award, American Society of Clinical Oncology (2008)
- Nadia's Gift, Nadia's Gift Foundation (2015)
- New Investigator Award, Stanford Cancer Institute (2011)
- Oncology Division Teaching Award, Stanford University School of Medicine (2010, 2012, 2013, 2014)
- San Francisco Bay Area Top Doctor, Medical Oncology, Castle Connolly (2017-2020)
- Visionary Award, Susan G. Komen San Francisco Bay Area (2019)
- Young Investigator Award, American Society of Clinical Oncology (2009)
Administrative Appointments
- ASCO Breast Cancer Adjuvant Chemotherapy and Targeted Therapy Guideline Adaptation Panel, American Society of Clinical Oncology (2015 - Present)
- Associate Director, Stanford Women's Cancer Center, Stanford Cancer Institute (2020 - Present)
- Breast Cancer Guidelines Panel, National Comprehensive Cancer Network (2014 - Present)
- Breast Cancer Maintenance of Certification Working Group, American Society of Clinical Oncology (2013 - 2014)
- Breast Oncology Protocol Review Committee Co-Chair, Stanford Cancer Institute (2015 - 2018)
- Director, Breast Cancer Program, Stanford Cancer Institute (2020 - Present)
- Komen Scholar, Susan G. Komen for the Cure (2015 - Present)
- Leader, Breast Cancer Clinical Care Program, Stanford Medicine (2020 - Present)
- Leader, Breast Cancer Clinical Research Group, Stanford Cancer Institute (2018 - Present)
- Medical Oncology SEP Committee, American Board of Internal Medicine (2014 - 2017)
- Program Committee, ASCO Breast Cancer Symposium (2010 - 2013)
- Scientific Program Committee, Triple Negative Breast Cancer/Cytotoxics/Local Therapy, American Society of Clinical Oncology (2010 - 2013)
- Scientific Review Committee, Stanford Cancer Institute (2016 - Present)
Publications
-
Phyllodes tumors of the breast: natural history, diagnosis, and treatment.
Telli, M. L., Horst, K. C., Guardino, A. E., Dirbas, F. M., & Carlson, R. W. (2007). Phyllodes tumors of the breast: natural history, diagnosis, and treatment. Journal of the National Comprehensive Cancer Network , 5(3), 324–30. -
Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007). Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. JOURNAL OF CLINICAL ONCOLOGY, 25(23), 3525–33. -
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613–1618. -
First-Line Chemotherapy for Metastatic Breast Cancer
Telli, M. L., & Carlson, R. W. (2009). First-Line Chemotherapy for Metastatic Breast Cancer. CLINICAL BREAST CANCER, 9, S66–S72. -
Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls
Gramatges, M. M., Telli, M. L., Balise, R., & Ford, J. M. (2010). Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 19(2), 605–13. -
Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California
Gomez, S. L., Lichtensztajn, D., Kurian, A. W., Telli, M. L., Chang, E. T., Keegan, T. H. M., … Clarke, C. A. (2010). Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California. JOURNAL OF CLINICAL ONCOLOGY, 28(10), E155–E157. -
Novel Treatment Approaches for Triple-Negative Breast Cancer
Telli, M. L., & Ford, J. M. (2010). Novel Treatment Approaches for Triple-Negative Breast Cancer. CLINICAL BREAST CANCER, 10, E16–E22. -
Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H. M., McClure, L. A., Lichtensztajn, D., … Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. BREAST CANCER RESEARCH AND TREATMENT, 127(2), 471–78. -
Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally?
Yoon, G. J., Telli, M. L., Kao, D. P., Matsuda, K. Y., Carlson, R. W., & Witteles, R. M. (2010). Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally? JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 56(20), 1644–50. -
PARP inhibitors in breast cancer.
Telli, M. L., & Ford, J. M. (2010). PARP inhibitors in breast cancer. Clinical Advances in Hematology & Oncology : H&O, 8(9), 629–35. -
Trastuzumab-Related Cardiac Dysfunction
Telli, M. L., & Witteles, R. M. (2011). Trastuzumab-Related Cardiac Dysfunction. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(2), 243–49. -
Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?
Witteles, R. M., Fowler, M. B., & Telli, M. L. (2011). Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented? HEART FAILURE CLINICS, 7(3), 333-? -
PARP inhibitors in cancer: moving beyond BRCA
Telli, M. L. (2011). PARP inhibitors in cancer: moving beyond BRCA. LANCET ONCOLOGY, 12(9), 827–828. -
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort
Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., Balmana, J., … Garber, J. E. (2012). Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. BREAST CANCER RESEARCH AND TREATMENT, 133(3), 1125–30. -
Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
Witteles, R. M., & Telli, M. (2012). Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned? JOURNAL OF CLINICAL ONCOLOGY, 30(16), 1916–18. -
Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
Powell, A. A., Talasaz, A. A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., … Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5). -
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome
Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., Ganjoo, K., … Telli, M. L. (2012). Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 939–42. -
Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer.
Palesh, O., Peppone, L., Innominato, P. F., Janelsins, M., Jeong, M., Sprod, L., … Mustian, K. (2012). Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nature and Science of Sleep, 4, 151–62. -
Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells
Yang, L. J., Guo, Y. L., Trygankova, O., Li, Q. Y., Maloney, J. A., Steinhauer, M., & Williamson, J. R. (1999). Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells. BIOCHEMICAL PHARMACOLOGY, 57(4), 425–432. -
Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. Journal of the American Medical Informatics Association , 20(6), 1059–66. -
Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer
Telli, M. L. (2013). Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(29). -
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, B., McPherson, L., … Kurian, A. W. (2013). A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. BREAST CANCER RESEARCH AND TREATMENT, electronic publication ahead of print, October 30. -
Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer.
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer. AMIA Summits on Translational Science Proceedings AMIA Summit on Translational Science, 2013, 62-? -
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang, H., Cohen, A. L., Krishnakumar, S., Wapnir, I. L., Veeriah, S., Deng, G., … Jeffrey, S. S. (2014). Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Research , 16(2), R36-? -
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Deng, G., Krishnakumar, S., Powell, A. A., Zhang, H., Mindrinos, M. N., Telli, M. L., … Jeffrey, S. S. (2014). Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer, 14, 456-? -
(18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru, A., Mosci, C., Shen, B., Chin, F. T., Mittra, E., Telli, M. L., & Gambhir, S. S. (2014). (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. Radiology, 273(2), 549–59. -
Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
Telli, M. (2014). Optimizing chemotherapy in triple-negative breast cancer: the role of platinum. American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting, 34, e37–42. -
The future of breast cancer systemic therapy: the next 10 years.
Telli, M. L., & Sledge, G. W. (2015). The future of breast cancer systemic therapy: the next 10 years. Journal of Molecular Medicine (Berlin, Germany), 93(2), 119–25. -
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., … Ford, J. M. (2015). Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Journal of Clinical Oncology , 33(17), 1895–1901. -
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
Watkins, J., Weekes, D., Shah, V., Gazinska, P., Joshi, S., Sidhu, B., … Tutt, A. N. J. (2015). Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. CANCER DISCOVERY, 5(5), 488–505. -
The role of platinum therapy in triple-negative breast cancer
Afghahi, A., & Telli, M. L. (2014). The role of platinum therapy in triple-negative breast cancer. Breast Cancer Management, 3(4). -
Breast Cancer, Version 1.2016.
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2015). Breast Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network : JNCCN, 13(12), 1475–85. -
Evolving treatment strategies for triple-negative breast cancer.
Telli, M. (2015). Evolving treatment strategies for triple-negative breast cancer. Journal of the National Comprehensive Cancer Network , 13(5), 652–654. -
Breast Cancer Version 2.2015
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2015). Breast Cancer Version 2.2015. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(4), 448–75. -
Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity
Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., … Wu, J. C. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. NATURE MEDICINE, 22(5), 547–56. -
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline
Denduluri, N., Somerfield, M. R., Eisen, A., Holloway, J. N., Hurria, A., King, T. A., … Wolff, A. C. (2016). Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. JOURNAL OF CLINICAL ONCOLOGY, 34(20), 2416–U186. -
Invasive Breast Cancer Version 1.2016 Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2016). Invasive Breast Cancer Version 1.2016 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(3), 324–54. -
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., … Richardson, A. L. (2016). Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research , 22(15), 3764–73. -
Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
Tsai, J., Bertoni, D., Hernandez-Boussard, T., Telli, M. L., & Wapnir, I. L. (2016). Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer. Annals of Surgical Oncology, 23(10), 3310–16. -
Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.
Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., … Telli, M. L. (2016). Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. Journal of Oncology Practice / American Society of Clinical Oncology, 12(8), 763–64. -
Breast Cancer After Hodgkin Lymphoma: The Price of Success.
Manzo, V., Dirbas, F., & Telli, M. L. (2016). Breast Cancer After Hodgkin Lymphoma: The Price of Success. Oncology (Williston Park, N.Y.), 30(12). -
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Isakoff, S. J., Puhalla, S., Domchek, S. M., Friedlander, M., Kaufman, B., Robson, M., … Shepherd, S. P. (2016). A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology , -? -
Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., … Telli, M. L. (2017). Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Genetics of triple-negative breast cancer: Implications for patient care.
Afghahi, A., Telli, M. L., & Kurian, A. W. (2016). Genetics of triple-negative breast cancer: Implications for patient care. Current Problems in Cancer, 40(2-4), 130–140. -
Reply to L. Del Mastro and A. Prat.
Denduluri, N., Somerfield, M. R., Eisen, A., Holloway, J. N., Hurria, A., King, T. A., … Wolff, A. C. (2017). Reply to L. Del Mastro and A. Prat. Journal of Clinical Oncology , JCO2016709758-? -
Outstanding Questions in the Clinical Management of Triple-Negative Breast Cancer.
Gruber, J. J., & Telli, M. L. (2017). Outstanding Questions in the Clinical Management of Triple-Negative Breast Cancer. Journal of Oncology Practice, 13(5), 305–7. -
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.
Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., … Ellis, M. J. (2017). Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2017). NCCN Guidelines Insights: Breast Cancer, Version 1.2017. Journal of the National Comprehensive Cancer Network , 15(4), 433–51. -
Assessing treatment response in triple-negative breast cancer from quantitative image analysis in perfusion magnetic resonance imaging.
Banerjee, I., Malladi, S., Lee, D., Depeursinge, A., Telli, M., Lipson, J., … Rubin, D. L. (2018). Assessing treatment response in triple-negative breast cancer from quantitative image analysis in perfusion magnetic resonance imaging. Journal of Medical Imaging (Bellingham, Wash.), 5(1), 011008. -
Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
Han, H. S., Diéras, V., Robson, M., Palácová, M., Marcom, P. K., Jager, A., … Puhalla, S. (2017). Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study. Annals of Oncology : Official Journal of the European Society for Medical Oncology. -
Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., … Kurian, A. W. (2018). Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Kornblum, N., Zhao, F., Manola, J., Klein, P., Ramaswamy, B., Brufsky, A., … Sparano, J. A. (2018). Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017769331. -
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Shead, D. A. (2018). Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 16(3), 310–20. -
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli, M. L., Hellyer, J., Audeh, W., Jensen, K. C., Bose, S., Timms, K. M., … Ford, J. M. (2018). Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Research and Treatment, 168(3), 625–30. -
Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
Doherty, M. R., Cheon, H. J., Junk, D. J., Vinayak, S., Varadan, V., Telli, M. L., … Jackson, M. W. (2017). Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 114(52), 13792–97. -
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Denduluri, N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S., Hassett, M., … Giorando, S. (2018). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology. -
Exploiting Homologous Recombination Deficiency in TNBC
Aleshin, A., & Telli, M. L. (2017). Exploiting Homologous Recombination Deficiency in TNBC. CURRENT BREAST CANCER REPORTS, 9(1), 52–59. -
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
Telli, M. L., Stover, D., Loi, S., Aparicio, S., Carey, L. A., Domchek, S. M., … Winer, E. P. (2018). Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Research and Treatment. -
Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy.
Kozak, M. M., Jacobson, C. E., von Eyben, R., Walck, E., Pollom, E. L., Telli, M., & Horst, K. C. (2018). Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy. Clinical Breast Cancer. -
Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
Kozak, M. M., Jacobson, C. E., von Eyben, R., Pollom, E. L., Telli, M., & Horst, K. C. (2018). Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response. Journal of the National Comprehensive Cancer Network : JNCCN, 16(7), 845–50. -
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Denduluri, N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S. L., Hassett, M. J., … Giordano, S. H. (2018). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018788604. -
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli, M. L., Stover, D. G., Loi, S., Aparicio, S., Carey, L. A., Domchek, S. M., … Winer, E. P. (2018). Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Research and Treatment. -
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Cruz, C., Llop-Guevara, A., Garber, J. E., Arun, B. K., Perez Fidalgo, J. A., Lluch, A., … Isakoff, S. J. (2018). Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018786558. -
A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E.-M. M., … Robson, M. E. (2018). A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
A four-gene decision tree signature classification of triple-negative breast cancer: Implications for targeted therapeutics.
Quist, J., Mirza, H., Cheang, M. C., Telli, M. L., O'Shaughnessy, J., Lord, C. J., … Grigoriadis, A. (2018). A four-gene decision tree signature classification of triple-negative breast cancer: Implications for targeted therapeutics. Molecular Cancer Therapeutics. -
Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.
Bardia, A., Parton, M., Kümmel, S., Estévez, L. G., Huang, C.-S. S., Cortés, J., … Kim, S.-B. B. (2018). Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017748392. -
Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way.
Telli, M. L., & Vinayak, S. (2019). Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way. Annals of Oncology : Official Journal of the European Society for Medical Oncology. -
NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
Goetz, M. P., Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Allison, K. H., … Kumar, R. (2019). NCCN Guidelines Insights: Breast Cancer, Version 3.2018. Journal of the National Comprehensive Cancer Network : JNCCN, 17(2), 118–26. -
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
Hurvitz, S. A., Quek, R. G., Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., … Wardley, A. M. (2018). Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. European Journal of Cancer (Oxford, England : 1990), 104, 160–168. -
Human Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Breast Cancer Patients.
Kitani, T., Ong, S.-G. G., Lam, C. K., Rhee, J.-W. W., Zhang, J. Z., Oikonomopoulos, A., … Wu, J. C. (2019). Human Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Breast Cancer Patients. Circulation. -
Induced Pluripotent Stem Cell-Based Cancer Vaccines.
Ouyang, X., Telli, M. L., & Wu, J. C. (2019). Induced Pluripotent Stem Cell-Based Cancer Vaccines. Frontiers in Immunology, 10, 1510. -
Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., … Telli, M. L. (2019). Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncology. -
NCCN Guidelines Updates: Breast Cancer.
Telli, M. L., Gradishar, W. J., & Ward, J. H. (2019). NCCN Guidelines Updates: Breast Cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 17(5.5), 552–555. -
Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer.
Scott, D., Friedman, S., Telli, M. L., & Kurian, A. W. (2019). Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer. Journal of Oncology Practice, JOP1900221. -
Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
Telli, M. L., Chu, C., Badve, S. S., Vinayak, S., Silver, D. P., Isakoff, S. J., … Richardson, A. L. (2019). Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., … Kumar, R. (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(4), 452–78. -
BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?
Telli, M. L. (2020). BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer? The Lancet. Oncology. -
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., … Harbeck, N. (2020). Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet (London, England), 396(10257), 1090–1100. -
Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy.
Telli, M. L., Nagata, H., Wapnir, I. L., Acharya, C., Zablotsky, K. E., Fox, B. A., … Crosby, E. J. (2021). Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
Vahdat, L. T., Schmid, P., Forero-Torres, A., Blackwell, K., Telli, M. L., Melisko, M., … Yardley, D. A. (2021). Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. NPJ Breast Cancer, 7(1), 57. -
NCCN Guidelines Insights: Breast Cancer, Version 4.2021.
Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., … Kumar, R. (2021). NCCN Guidelines Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network : JNCCN, 19(5), 484–493. -
A Phase 1 Dose-Escalation and Expansion Study of Telaglenastat in Patients With Advanced or Metastatic Solid Tumors.
Harding, J. J., Telli, M., Munster, P., Voss, M. H., Infante, J. R., DeMichele, A., … Meric-Bernstam, F. (2021). A Phase 1 Dose-Escalation and Expansion Study of Telaglenastat in Patients With Advanced or Metastatic Solid Tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt, A. N., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., … Geyer, C. E. (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. The New England Journal of Medicine, 384(25), 2394–2405. -
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
Denduluri, N., Somerfield, M. R., Chavez-MacGregor, M., Comander, A. H., Dayao, Z., Eisen, A., … Giordano, S. H. (2021). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 39(6), 685–693. -
Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.
Meric-Bernstam, F., Tannir, N. M., Lliopoulos, O., Lee, R. J., Telli, M. L., Fan, A. C., … Bauer, T. M. (2022). Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
Henry, N. L., Somerfield, M. R., Dayao, Z., Elias, A., Kalinsky, K., McShane, L. M., … DeMichele, A. (2022). Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2201063. -
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., … Kumar, R. (2022). Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 20(6), 691–722. -
Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas, J., Loibl, S., Denkert, C., Telli, M., & Loi, S. (2022). Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 42, 1–13. -
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Telli, M. L., Tolaney, S. M., Shapiro, G. I., Middleton, M., Lord, S. R., Arkenau, H. T., … Plummer, R. (2022). Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. NPJ Breast Cancer, 8(1), 45. -
Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
Freedman, R. A., Graff, S. L., Somerfield, M. R., Telli, M. L., Wolff, A. C., & Giordano, S. H. (2022). Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncology Practice, 18(7), 516–519. -
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., … O'Shaughnessy, J. (2021). Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 32(8), 994–1004. -
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
Gruber, J. J., Afghahi, A., Timms, K., DeWees, A., Gross, W., Aushev, V. N., … Telli, M. L. (2022). A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nature Cancer. -
Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta, T., Vinayak, S., & Telli, M. (2022). Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Research and Treatment. -
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., … Tutt, A. N. (2022). Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology. -
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
Schram, A. M., Colombo, N., Arrowsmith, E., Narayan, V., Yonemori, K., Scambia, G., … Yap, T. A. (2022). Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial. JAMA Oncology. -
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap, T. A., Bardia, A., Dvorkin, M., Galsky, M. D., Beck, J. T., Wise, D. R., … Konstantinopoulos, P. A. (2022). Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncology.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors »
- Study of ABT-165 in Subjects With Advanced Solid Tumors »
- An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy »
- Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI »
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer »
- PALbociclib CoLlaborative Adjuvant Study »
- Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer »
- Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) »
Practice Locations
Breast Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Breast Cancer Program in Palo Alto
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Stanford Women's Cancer Center Palo Alto, CA
Palo Alto, CA
Stanford Women's Cancer Center
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(147 reviews)
I love her. So patient and kind and very clear.
Dr Telli's expertise and kind encouragement were invaluable
Dr Telli is awesomely wonderful.
I really appreciated Dr. Telli's thoughtful insights about my case and potential treatment options, pending further data. She was compassionate and also pointed out resources that could provide psychological / emotional support when dealing with a new diagnosis, which sound helpful.
Dr Telli is a wonderful doctor. She always takes the time to explain things and is very caring
As a doctor I only consulted with, I felt she cared about my case and my health and made herself available for follow up. I am so grateful I found her and I highly value her opinion and recommendations for my treatment and care.
Dr. Telli was most helpful and, above all, she spoke slowly and distinctly as she described my cancerous breast and the likely treatment. I appreciated her mentioning I could call her back with questions if they arise.
Dr. Telli is the very best. She is calm, patient and very knowledgeable. Although I often have to wait some time to see her, she is well worth the wait. She does not rush me. I feel I have her undivided attention. During in office visits she is so very gentle. She has a touch like a butterfly. I feel so very fortunate to have her for my doctor.
I have been well pleased with my cancer treatment at Stanford. Dr. Telli and her team have certainly made my experience with cancer a positive one~so much care and compassion with every appointment .
terrific doctor
Telli is wonderful, truly amazing combination of smart and kind. She also goes out of her way to teach her patients what is going on, which I've never had before (and I've met many oncologists). She has wonderful bedside manner and she's brilliant
Although I was initially disturbed by not knowing what to do about the timing, The wait was very much worth it. When Dr Telli called It was more than worth the wait. Her information was very clear. She addressed all my concerns and suggested a path forward that was very comfortable for me. I am very very grateful that she made the time to talk to me. It was not rushed and even though she was extremely busy I felt I had her full attention. I also wish to compliment her associate(I'm sorry I forgot her name) that got our visit started. She also took her time with me.
Overall if you could somehow sort out the process issues when an appointment is delayed everything is perfect. Excellent experience !!
Dr Telli is the best.
Dr. Telli is wonderful, caring and compassionate.
Very helpful and professional
She is the very best--cream of the crop. I feel so blessed to have her as my oncologist. She has a wonderful way with patients. She is very kind, patient and attentive. I trust her implicitly. Although I have to wait sometimes for her, the wait is well worth it. Did I make it clear that she is the very best!?!
Melinda Telli is so knowledgeable and while I watched her present in Texas to other doctors and didn’t understand a lot of what they were saying, she was able to break down her recommendation for my treatment in words I could understand. I am so thankful for Dr. Telli’s advice and help with my treatment!
Only one comment.
She is an outstanding physician and communicator.
Dr. Telli is the best!
Dr Telli is a brilliant and compassionate breast oncologist. I'm very grateful to have her leading my care!!!
Dr. Telli needs a bonus! So does Stanford Cancer Center. I am an experienced healthcare provider with high expectations. This team has exceeded all my expectations for care. I have told Dr. Telli this. She is an asset to Stanford Medicine and truly cares for and about her patients. A passion for what she does. Rare to find in a lot of physicians these days.
I feel fortunate to have had her during a journey I did not expect to be on.
STANFORD should do everything in their power to retain her and her staff for years to come. A great physician and beautiful human being.
Dr. Telli was personable, clearly explained everything, and was efficient with the time we had together. I'm very grateful I was able to consult with her.
Dr Telli is excellent. I have full confidence in her care and my plan moving forward.
She was very personable, took her time explaining things and answered all of my questions to my satisfaction.
Dr Telli is amazing!
I recommend stanford every opportunity i have
I very highly recommend Dr Telli! She is my hero!
Dr. Telli is fabulous.
Dr. Telli is a very caring doctor and has very good bedside manner.
Dr. Telli is the best!
Dr. Telli has been wonderful. While I would like to not have to recommend her but if I had any friend or family member who needs to see an oncologist I would recommend her without hesitation.
Dr. Telli is an excellent doctor. I am so glad to have her as my oncologist!
Dr. Telli is a very good and caring physician. She has never rushed me and always answers my questions. I highly recommend her.
Melinda Telli is great caring, thorough and easy to talk to.
Dr. Telli is incredibly caring & warm. She listens well & is thorough on her examination & explanations.
Dr. Telli is so calm, friendly & warm, even when very busy, she spends the time needed. Remembers me when I come in, so knowledgeable. I travel from out of state to see her & it is well worth it!
Dr. Telli is fabulous!
These ratings are for Dr. Melinda Telli.
Dr. Telli is wonderful. Very knowledgeable & caring. I have utmost confidence in her.
Dr. Telli is amazing. Her knowledge of the latest cancer research, her attention to detail saved my life. I love Dr. T.
Very thorough. Very patient with my questions. Very knowledgeable. I travel far to see her but it is worth it.
Dr. Telli is kind, caring, and takes time to address all issues. I travel from out of state to see her and it is well worth it.
Dr. Telli is fabulous! I feel she genuinely cares about me.
Dr. Telli is remarkable. I would describe her as a "Stanford Brilliant." She is a master at her craft.
Dr. Telli is an excellent doctor with great bedside manner. I am very lucky she is my doctor.
The provider was calm, respectful, & informative. She was very clear explaining options to me. I didn't feel rushed & believe she gave me her utmost attention.
Very nice care, loving kindness, willing to listen. Patiently explain.
Dr. Telli and Kiran were an excellent team. They were both compassionate, respectful and extremely competent. I have never been more pleased with a medical appointment. I felt listened to, and they had innovative therapy for me to try. They spent plenty of unhurried time with me. Excellent appointment!
I highly recommend Dr. Telli & Erin (PA). They are both awesome.
Dr. Telli and her staff are amazing. They made us feel like people not a number. She spent time with us and explained things in a way we could understand.
Dr. Telli is the best!
I was extremely impressed with the patience, care, and genuine attentiveness that Dr. Telli showed during my appointment. This is especially true since she entered my room around 7 p.m. and stayed for an hour, and I'm sure she had already had a long, busy day.
Dr. Telli is an excellent physician.
Dr. Telli is a VERY caring genuine professional. Makes you feel very comfortable explains thing very clearly so I understand it.
Dr. Telli is very knowledgeable & compassionate. I feel confident w/her.
Dr. Telli is a great doctor with a very good bedside manner. I highly recommend her.
Dr. Telli was head and shoulders better than any of the other 3 oncologists I have met with.
Really appreciate how thorough Dr. Telli is. So knowledgeable as well.
Dr. Telli is extremely caring and present during my appointment(s). I have the utmost confidence in her!! Thank you for your excellence in all areas, Dr. Telli!
Dr. Telli is excellent.
Dr. Telli is fabulous.
Dr. Telli was amazing, every thing I had hoped for and more. I left her office with valuable information & hope. PA Erin was also awesome. So thankful for my Stanford visit.
Doc was wonderful, very informative.
Both Dr. Telli & NP were thorough, friendly, & informative.
I love Dr. Telli she is the absolute BEST!!
I love Melinda Telli and Jessica Foran. The CARE they show for me is unbelievable.
Everyone is so nice. Friendly and professional.
Dr. Telli was not only personable but thorough.
Dr. Telli always takes good care of me. She has very good bedside manner. She's a great doctor.
I had an excellent team of care providers at Stanford.
I'm so happy having Dr. Telli as my breast oncologist cause she's so compassionate & understanding with untiring efforts to heal me with her patience that helps me continue with my fight against cancer. My appreciation & eternal gratitude to her! Thanks very much.
I appreciated the amount of information given to me. Almost all my questions were answered before I asked them.
Dr. Telli and team were very attentive explained everything in detail and made me feel comfortable.
Dr. Telli is amazing! Could not have asked for any better care.
Dr. Telli is an excellent care provider.
Dr. Telli is a gem. I feel blessed to have her on my team.
Best physician I have ever had.
Dr. Telli is a very good doctor with a very caring bed-side manner. I highly recommend her.
Excellent provider but needed to wait 2 hrs. for visit.
Jessica Foran and Melinda Telli are superlative givers of care. I cannot express how positively they have both impacted my life during and post cancer treatment.
Dr. Telli was so thorough & professional. She took her time and answered all my questions. She was able to provide studies to reinforce her recommendations for my care.
I love the dr.!!!
Excellent care in explaining options that were easy to understand and explaining details and status of my prognosis.
Excellent physician!
Dr. Telli is professional, warm, and caring - an IDEAL care provider!
Have always had good experiences/contacts at this facility.
Dr. Telli, Josh and Pei-ter are a great and compassionate team.
Dr. Telli is the best physician - she explained - everything thoroughly and was very patient.
Dr. Telli provides reassurance and is very knowledgeable on treatment of breast cancer.
Dr. Telli is the most compassionate and kind doctor I have ever met.
Dr. Melinda Telli is a saint - no, really!!
They make me feel confident in asking about any concern I have.
Dr. Telli is a fantastic doctor. She has a very good bedside manner and very caring.
Love Dr. Telli!
Very caring, outstanding doctor.
Thanks to these doctors, this place and their care I'm still alive. Thank you.
I needed to discuss doctor's recommendation in more detail and to ask several significant questions. The follow-up by doctor after the appt. was poor.
Dr. Telli always provides a complete evaluation, not just related to the purpose of the visit. She is the perfect blend of the art and science of medicine.
Dr. Telli is great!
Explained things very clearly. Drew diagrams to explain.
Dr. Telli is a truly wonderful physician. She has genuine care and concern and we are very grateful to be in her care.
Dr. Telli is wonderful and her fellow is equally as talented.
Dr. Telli very compassionate & kind. Very thorough.
Dr. Telli is excellent, as are Greg (her intern) Larissa & Kiran. All very good at explaining my diagnosis, medications & what to expect!
Good.
Dr Telli and staff are wonderful. Well worth the drive from Reno!
Exceptionally high level of compassion; provided a very clear rationale for next steps in my medical care.
Dr. Telli is technically an excellent oncologist, but the human side of her approach puts her in a completely different class of other doctor's I've encountered. She is truly spectacular.
Dr. Telli and her associate spent a good deal of time w/ me in examination, analysis and preparation of a Tx. plan, and later in their explanations of this plan. I had a very good experience w/ Dr. Telli and her team.
Dr. Telli and Larissa are the best. My husband felt so well informed & supported he said he wish that he had had a tape of the conversation.
Dr. Telli is professional, caring. Very happy to have her on my corner.
Dr. Telli is by far the finest doc. I have ever dealt with as cared for by heaps of empathy and delightful person! I have considerable experience with Stanford across several disciplines - She is THE BEST.
I love Dr. Telli - she saved my life.
Dr. Telli is great. She also has a wonderful touch. We (my husband comes with) travel quite a ways to see her.
I have much confidence in Doctor Telli, Melinda because she doesn't leave me without treatment.
These "very good" are all true. Dr.Waprin & Dr.Telli & their staff were terrific.
Dr Telli is fantastic care provider. I highly recommend her and thankful to have her as my Oncologist after a long search.
Extremely informative & pleasant -
Dr. Telli excellent.
Both Dr. Telli and Dr. Afghahi are helpful and willing to discuss any questions I have. I am in a clinic trial with them but wish I were able to transfer all of my care. However, distant makes that impossible.
Dr. Telli is an amazing doctor!! I can't say enough good about her.
Wonderful experience.
This was the first time I had met Dr. Telli. I found her to be very knowledgeable, professional, caring, intelligent, clear and pleasant to deal with.
I feel comfortable and I have trust in Dr. Telli, which gives me peace of mind.
My team take very good care of me.
Extremely pleased with Dr. Telli & Stanford on the whole.
Dr. Telli is amazing. So professional, yet compassionate and encouraging.
Dr. Melinda Telli has just the right balance of intelligent, specific knowledge and the ability to convey it in terms we could understand. Great "bedside" manner. TOTALLY professional.
I always feel fully satisfied that I have been completely understood & given excellent treatment.
Excellent Dr. Telli is the BEST.
Dr. Telli is what every Dr. should be. She is wonderful.
Dr. Telli is an excellent care provider, very knowledgeable, up-to-date, caring, easy to understand.
She is my life line to emotional and health care.
Dr. Telli is very kind, informative and empathetic. She has an excellent bedside manner.
Dr. Telli should be cloned - all drs. should be her. She is wonderful!
Good experience.
Dr. Telli was wonderful. I came to her for a second opinion and she was much more helpful than my regular doctor.
Dr. Melinda Telli is exceptional. I would never go back to my previous oncologist. I totally trust her & think she's an outstanding doctor.
Dr. Telli is an amazing listener, a warm & engaging person, & solution-focused.
Dr. Telli made decision for treatment & explained why.
Dr. Telli spent quality time with me and covered all my concerns. I felt very comforted by her manner and knowledge.
My provider is great!! Always makes me feel I am HER main concern - And my total well being - Not just the cancer.
Dr. Telli is everything we hoped for & more.
I love Melinda Telli and all of her staff -- She is a very compassionate doctor & spends a great deal of time w/me.
Both the PA & Dr. Telli were very clean & helpful in explaining options to me.
Dr. Telli and her staff are the best!
Very good.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or e-mail the Referral Center at ReferralCenter@stanfordhealthcare.org
- Send referrals online
- View referral status
- Access medical records